Impact Education, LLC’s Post

📌 Earlier diagnosis and more effective treatment of chronic kidney disease (CKD) can reduce patient and caregiver absenteeism, increase the ability to work and promote long-term productivity. 🌀   Learn more about the economic impact of CKD: https://learn.az/6187kk1DP   #ForKidneyHealth  Global Patient Alliance for Kidney Health AstraZeneca

The Kidney Disease: Improving Global Outcomes (KDIGO) organization, established in 2003, aims to enhance kidney disease care globally. Central to its mission are global clinical practice guidelines. An updated KDIGO Clinical Practice Guideline for Chronic Kidney Disease (CKD) was recently introduced to complement existing guidelines. This updated guideline, developed over 2-3 years, involves a rigorous process detailed in the KDIGO Methods Manual. It includes screening for conflicts of interest, public engagement, and systematic literature reviews by an independent Evidence Review Team. The guideline evolves with emerging evidence and aims to provide clear, evidence-based recommendations for CKD diagnosis and management. KDIGO expresses gratitude to all contributors, emphasizing the commitment to excellence in patient care. Link to the 2024 KDIGO update: https://lnkd.in/gDVT83EE #KDIGO2024 #ClinicalPracticeGuideline #ESRD #CKD #ESKD #Kidneydisease #RenalFailure #RenalReplacment #dialysis #hemodialysis #whatis

Newly launched Australian IBD whitepaper- titled ‘IBD: Addressing the "hidden" disease with innovative, multidisciplinary and patient centric care’, provides a springboard for clinicians and patient advocates to explore the key care challenges in Australia and tangible solutions to drive better patient outcomes. These include: • Facilitating speedy diagnosis and specialist referrals • Delivering integrated multidisciplinary care • Ensuring a focus on patient-centric care • Improving access to novel treatments • Supporting innovations in treatment and monitoring https://lnkd.in/gT463SMC IBD Practice Review Issue 16 - Content has been reviewed by Associate Professor Britt Christensen https://lnkd.in/gsHS2N2D

VIDA's AI-driven mucus plug analysis will be featured in 5 #ATS2024 abstracts. In this analysis of #SARP patients by Peterson et al., a regional association between mucus plugging and downstream air trapping was evident in subjects with severe plugs. These results add to the growing evidence that plugs could be targeted with therapies to improve downstream air trapping in patients with asthma. https://hubs.ly/Q02wxnyz0 Meet with VIDA at ATS: https://hubs.ly/Q02wxrxs0 #mucusplugs #mucusplugging #asthma #digitalbiomarkers

📢 Today, we are attending the high-level policy event "Towards a Patient-Centred EU Mandate: Health Policy with and for Patients" organised by the European Patients' Forum! 💡 #DidYouKnow that #patients rely on the off patent medicines industry for over 70% of dispensed medicines, treating major chronic diseases like cancer, cardiovascular disease, auto immune conditions and diabetes? 👥 Together, we must ensure timely and equitable #access across member states and secure the availability of essential medicines and the resources needed to produce them in the EU. Patient involvement and access to care are crucial for advancing comprehensive solutions for better #healthcare outcomes. 🏥 🙌 Big thanks to European Patients' Forum for hosting the event and looking forward to working together on shaping health policy! #Access4All #Vote4Patients #MedicinesForEurope #PharmaLegislation

Thank you for another year of participation in HIGR! By sharing your HI journey, you provide insight into the HI patient and caregiver experience that can shape future research. Read the 2023 HIGR Annual Report at https://bit.ly/higr-23 !⁠ ⁠ If you haven’t yet joined HIGR, do so today (https://lnkd.in/ewfaCRp) so that YOUR experiences can be included in future reporting. The success of the registry depends on all of us.⁠ ⁠ ⁠ #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

Gain valuable insights into current and evolving treatments for inherited blood disorders like hemophilia, sickle cell disease and thalassemia in JMCP. AMCP's Market Insights program convened a panel of experts from national and regional health plans, integrated health care systems, employer benefits groups, clinical experts, the Centers for Disease Control and Prevention, and patient advocacy organizations to provide strategies for managed care organizations to manage innovative treatments for inherited blood disorders, which are crucial for evaluating long-term effectiveness and safety, ongoing decision-making, and cost management. https://bit.ly/4cQEUgC #healthcare #blooddisorder #managedcare #pharmacy

What are the key clinical examination findings in patients with skin of color and atopic dermatitis? Dr. Andrew Alexis shares valuable insights on how to accurately assess atopic dermatitis in these patients, highlighting key strategies for a comprehensive evaluation and stressing the importance of not underestimating the severity of the disease. Learn more: https://e.lilly/3X2cV8B #AtopicDermatitis

Take a look at the latest report from the HI Global Registry, and learn more about life with hyperinsulinism at every stage.

Today we recognize the estimated 400 million people globally living with a rare disease. We know there is much work ahead to address unmet medical needs of these patients and that means securing a timely diagnosis, effectively treating their symptoms, but also improving their lives as a whole. So important that innovations emerge to help people with rare diseases live better, enabling greater autonomy and more quality time with the people they love, doing activities that bring them joy.   Many patients with rare, chronic and complex diseases such as primary immunodeficiencies depend on plasma-derived therapies, requiring frequent and life-long treatment. With therapeutic advances such as subcutaneous immunoglobulin treatment, those patients now have the option to self-administer at home, which can already contribute substantially to improving their lives. We need to continue investing as an industry to shorten infusion time and ease overall burden of IG administration, whilst developing more holistic digital solutions that help patients better manage their disease and treatment.   This #RareDiseaseDay, it’s important for the healthcare ecosystem to consider the whole patient, focusing both on transformative therapies to change the treatment paradigm for the future, but also meeting patients where they are today with innovations to improve their treatment experience.   #RareDiseaseDay #Plasma #PlasmaDerivedTherapies #Innovation